×
-0.000953213316219493 -0.000954432259078975 8.5326000172458E-06 -0.000954432259078975 -0.000832537973117529 -0.000954432259078975 -0.00071064368715591 -0.00010117225734816
Stockreport

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

ADVANCED ACCELERATOR APPLICATIONS SA AMERICAN DE (AAAP)  More Company Research Source: GlobeNewswire
Last advanced accelerator applications sa american de earnings: 8/31 07:00 am Check Earnings Report
PDF First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients Lutathera (lutetium Lu 177 dotatate) vial picture PFS graphic Lutathera (lutetium Lu 177 dotatate) mechanism of action picture LUTATHERA® marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) SAINT-GENIS-POUILLY, France, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications [Read more]

IMPACT SNAPSHOT EVENT TIME: AAAP
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS